Biotechnology

Novartis spends billions in 2025
  1. Biotechnology

Novartis spends billions in 2025

Newsletter Signup – Under Article / In Page “*” indicates required fields The year 2024 was regarded as a reset year with lackluster deal performance in the biopharma industry. This year was predicted to witness a surge in mergers and acquisitions (M&As) deals in the sector and in the latter half of the year, the pharma giant Novartis has struck big.  Novartis expanding cardiovascular research Novartis buys Tourmaline […]
Written by
Cystein as specific target for payloads in Tubulis ADC plattform
  1. Biotechnology

Tubulis secures €308m in record-breaking Series C financing  

Munich-based biotech Tubulis has closed a €308m (US$361m) Series C financing round – the largest of its kind for a European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The round was led by Venrock Healthcare Capital Partners, joined by new investors Wellington […]
Written by
Unraveling Ageing-Parkinson’s Link: PD-AGE Advances
  1. Biotechnology

Unraveling Ageing-Parkinson’s Link: PD-AGE Advances

In the rapidly evolving field of neurodegenerative disease research, Parkinson’s disease (PD) remains a focal point due to its complex interplay with the ageing process. A pioneering initiative led by the PD-AGE network seeks to illuminate this nexus through a groundbreaking study that emphasizes the urgent need for standardisation in in vitro models and experimental […]
Written by
The biggest biotech funding rounds in September 2025
  1. Biotechnology

The biggest biotech funding rounds in September 2025

Newsletter Signup – Under Article / In Page “*” indicates required fields The companies uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in […]
Written by
Vaccine
  1. Biotechnology

MSD Secures Option on EVX-B3

Under the agreement, MSD will assume full responsibility and carry all costs for the further development of the EVX-B3 vaccine. The vaccine is designed to combat pathogens that cause opportunistic, recurrent infections, such as S. aureus, Enterococcus sp., and uropathogenic E. coli. So far, the companies have not disclosed further details, but the vaccine is reportedly […]
Written by
blank
  1. Biotechnology

“‘Youth Molecule’ Shows Promise in Enhancing Quality of Life for

In a groundbreaking expert consensus published in Nature Aging, a collective of over 25 internationally renowned scientists and clinicians have shed new light on the pivotal role of nicotinamide adenine dinucleotide (NAD⁺) in aging biology and metabolic health. This comprehensive review comes as the scientific community intensifies efforts to decipher how modulation of NAD⁺ metabolism […]
Written by

Good Reads

Worlwide

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.